{
  "id": "5e3a6c49b5b409ea53000017",
  "type": "yesno",
  "question": "Is Verubecestat effective for Alzheimer's Disease?",
  "ideal_answer": "No. Verubecestat did not reduce cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease and was associated with treatment-related adverse events.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/31423903",
    "http://www.ncbi.nlm.nih.gov/pubmed/31387606",
    "http://www.ncbi.nlm.nih.gov/pubmed/28749667",
    "http://www.ncbi.nlm.nih.gov/pubmed/29719179",
    "http://www.ncbi.nlm.nih.gov/pubmed/30970186",
    "http://www.ncbi.nlm.nih.gov/pubmed/30347431"
  ],
  "snippets": [
    {
      "text": "The lack of efficacy of verubecestat in mild-to-moderate AD raises important questions about the timing of intervention with BACE-1 inhibitors, and anti-amyloid therapies in general, in AD treatment. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28749667",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Verubecestat did not reduce cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease and was associated with treatment-related adverse events.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29719179",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These results support the continued global development of verubecestat as a potential disease-modifying agent for Japanese and non-Japanese subjects who are at-risk for developing AD. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30347431",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS\n\nVerubecestat did not reduce cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease and was associated with treatment-related adverse events.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29719179",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS\n\nVerubecestat did not improve clinical ratings of dementia among patients with prodromal Alzheimer's disease, and some measures suggested that cognition and daily function were worse among patients who received verubecestat than among those who received placebo.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30970186",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "However, in the EPOCH trial of verubecestat in mild-to-moderate Alzheimer's disease, it was not beneficial and increased adverse effects.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31423903",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In APECS, verubecestat 40 mg worsened cognition and increased adverse effects.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31423903",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The lack of efficacy of verubecestat in mild-to-moderate AD raises important questions about the timing of intervention with BACE-1 inhibitors , and anti-amyloid therapies in general , in AD treatment . ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28749667",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Verubecestat , a BACE1 inhibitor that reduces A\u03b2 levels in the cerebrospinal fluid of humans , was not effective in a phase 3 trial ( EPOCH ) of mild-to-moderate AD and was associated with adverse events . ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31387606",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Lessons that can be learnt from the failure of verubecestat in Alzheimer 's disease .",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31423903",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CONCLUSIONS\nVerubecestat did not improve clinical ratings of dementia among patients with prodromal Alzheimer's disease, and some measures suggested that cognition and daily function were worse among patients who received verubecestat than among those who received placebo.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30970186",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In APECS, verubecestat 40 mg worsened cognition and increased adverse effects.Expert opinion: In recruiting subjects to clinical trials in Alzheimer's disease, a clinical diagnosis involving the measurement of A\u03b2 should be undertaken for all subjects, as this may help to clarify the findings.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31423903",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In my opinion, the failure of verubecestat in EPOCH and APECS probably could have been avoided if a safety and potential efficacy trial (phase 2) had been completed prior to starting phase 3.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31423903",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Verubecestat was associated with increased risk for several types of adverse events.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31387606",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Verubecestat did not improve clinical ratings of dementia among patients with prodromal Alzheimer's disease, and some measures suggested that cognition and daily function were worse among patients who received verubecestat than among those who received placebo. (",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30970186",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Verubecestat did not reduce cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease and was associated with treatment-related adverse events. (",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29719179",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}